COPD: Early diagnosis and treatment to slow disease progression

International Journal of Clinical Practice

Volumn 69, Issue 3, 2015, Pages 336-349

  Welte, T ^a   Vogelmeier, C ^b   Papi, A ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; SHORT ACTING DRUG; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

AIRWAY OBSTRUCTION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; COUGHING; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; EDUCATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERINFLATION; LUNG FUNCTION; MORTALITY; MUSCLE DISEASE; MUSCLE STRESS; MUSCLE WEAKNESS; PHYSICAL INACTIVITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDENTARY LIFESTYLE; SMOKING; SMOKING CESSATION; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYMPTOM; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; WHEEZING; DISEASE MANAGEMENT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

DISEASE MANAGEMENT; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84923535689     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12522     Document Type: Review

References (77)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2014. www.goldcopd.com (accessed January 2014).
2. Buist AS, Vollmer WM, McBurnie MA,. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12: 703-8.
3. World Health Statistics 2008. http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf (accessed January 2014).
4. Anzueto A,. Impact of exacerbations on COPD. Eur Respir Rev 2010; 19: 113-8.
5. British Lung Foundation. Invisible lives. Chronic obstructive lung disease (COPD)-finding the missing millions, 2010. http://www.lunguk.org (accessed April 2013).
6. Fletcher C, Peto R,. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-8.
7. Kohansal R, Martinez-Camblor P, Agustí A, Buist AS, Mannino DM, Soriano JB,. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180: 3-10.
8. Mannino DM, Buist AS,. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-73.
9. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2010. www.goldcopd.com (accessed April 2013).
10. D'Urzo A,. Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy. Clin Pract 2013; 10: 481-92.
11. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ,. COPD screening efforts in primary care: what is the yield? Prim Care Respir J 2007; 16: 41-8.
12. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-8.
13. Van den Boom G, Rutten-van Mölken MP, Tirimanna PR, van Schayck CP, Folgering H, van Weel C,. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J 1998; 11: 67-72.
14. Barnett M,. Chronic obstructive pulmonary disease: a phenomenological study of patients' experiences. J Clin Nurs 2005; 14: 805-12.
15. Shahab L, Jarvis MJ, Britton J, West R,. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61: 1043-7.
16. Agusti A, Calverley PA, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
17. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T,. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008; 63: 768-74.
18. Troosters T, Sciurba F, Battaglia S, et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 2010; 104: 1005-11.
19. Ora J, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O'Donnell DE,. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. Am J Respir Crit Care Med 2009; 180: 964-71.
20. Mannino DM, Doherty DE, Buist AS,. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100: 115-22.
21. Ofir D, Laveneziana P, Webb KA, Lam YM, O'Donnell DE,. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2008; 177: 622-9.
22. Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M,. Factors associated with good self-rated health and quality of life in subjects with self-reported COPD. Int J Chron Obstruct Pulmon Dis 2011; 6: 511-9.
23. ZuWallack RL,. Functional status and survival in COPD. Monaldi Arch Chest Dis 2003; 59: 230-3.
24. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antõ JM,. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-8.
25. Garcia-Aymerich J, Serra I, Gõmez FP, et al. Physical activity and clinical and functional status in COPD. Chest 2009; 136: 62-70.
26. Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H,. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011; 140: 331-42.
27. Watz H, Waschki B, Meyer T, Magnussen H,. Physical activity in patients with COPD. Eur Respir J 2009; 33: 262-72.
28. Reardon JZ, Lareau SC, ZuWallack R,. Functional status and quality of life in chronic obstructive pulmonary disease. Am J Med 2006; 119: S32-7.
29. ZuWallack R,. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. COPD 2007; 4: 293-7.
30. Shrikrishna D, Patel M, Tanner R, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012; 40: 1115-22.
31. Eisner MD, Blanc PD, Yelin EH, et al. COPD as a systemic disease: impact on physical functional limitations. Am J Med 2008; 121: 789-96.
32. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J 2010; 38: 81-8.
33. O'Reilly JF, Williams AE, Holt K, Rice L,. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006; 15: 346-53.
34. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
35. Langsetmo L, Platt RW, Ernst P, Bourbeau J,. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177: 396-401.
36. Greenberg SB, Allen M, Wilson J, Atmar RL,. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 167-73.
37. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5: 235-56.
38. Fabbri LM, Rabe KF,. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-9.
39. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-12.
40. Omachi TA, Katz PP, Yelin EH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med 2009; 122 (778): e9-15.
41. Vestbo J, Sørensen T, Lange P, Brix A, Torre P, Viskum K,. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
42. Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-53.
43. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK,. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
44. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-90.
45. Bossé R, Sparrow D, Garvey AJ, Costa PT Jr, Weiss ST, Rowe JW,. Cigarette smoking, aging, and decline in pulmonary function: A longitudinal study. Arch Environ Health 1980; 35: 247-52.
46. Vestbo J, Edwards LD, Scanlon PD, et al. ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92.
47. ® trial. COPD 2012; 9: 289-96.
48. 1. The Lung Health Study. JAMA 1994; 272: 1497-505.
49. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
50. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP,. UPLIFT Investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-8.
51. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al.; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009; 151: 517-27.
52. Decramer M, Cooper CB,. Treatment of COPD: the sooner the better? Thorax 2010; 65: 837-41.
53. Griffin MR, Coffey CS, Neuzil KM, Mitchel EF Jr, Wright PF, Edwards KM,. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med 2002; 162: 1229-36.
54. Yap FH, Ho PL, Lam KF, Chan PK, Cheng YH, Peiris JS,. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza season in Hong Kong. J Med Virol 2004; 73: 617-23.
55. Hass H, Morris JF, Samson S, Kilbourn JP, Kim PJ,. Bacterial flora of the respiratory tract in chronic bronchitis: comparison of transtracheal, fiberoptic, and oropharyngeal sampling methods. Am Rev Respir Dis 1977; 116: 41-7.
56. Sethi S, Evans N, Grant BJ, Murphy TF,. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-71.
57. Pesek R, Lockey R,. Vaccination of adults with asthma and COPD. Allergy 2011; 66: 25-31.
58. Anthonisen NR, Connett JE, Murray RP,. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-9.
59. Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778-85.
60. Kanner RE, Connett JE, Williams DE, Buist AS,. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med 1999; 106: 410-16.
61. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.
62. Decramer M, Rossi A, Lawrence D, McBryan D,. Indacaterol therapy in patients not receiving other maintenance treatment. Respir Med 2012; 106: 1706-14.
63. Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D,. Effects of long-Acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med 2013; 107: 223-32.
64. Kerstjens H, Kornmann O, Deslée G, Young D, Lawrence D, McBryan D,. Once-daily indacaterol 150 μg or 300 μg and other bronchodilators in COPD patients of GOLD 2011 groups A and B. Eur Respir J 2013; 42 (Suppl. 57): 144s. Abstract P758.
65. Dusser D, Bravo ML, Iacono P,. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-55.
66. ® trial. Eur Respir J 2010; 36: 65-73.
67. D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P,. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin 2014; 30: 493-508.
68. O'Donnell DE, Laveneziana P, Ora J, Webb KA, Lam YM, Ofir D,. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax 2009; 64: 216-23.
69. Calverley PM, Anderson JA, Celli B, et al. TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
70. Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
71. Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M,. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med 2010; 104: 1659-67.
72. National Institute for Health and Care Excellence (NICE). Chronic obstructive pulmonary disease (updated) CG101, June 2010. http://guidance.nice.org.uk/cg101 (accessed 17 June 2014).
73. Price D, Crockett A, Arne M, Garbe B, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J 2009; 18: 216-23.
74. Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med 2014; 24: 14003.
75. Maltais F, Dennis N, Chan CK,. Rationale for earlier treatment in COPD: a systematic review of published literature in mild-to-moderate COPD. COPD 2013; 10: 79-103.
76. van Grunsven P, Schermer T, Akkermans R, et al. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results from the DIMCA study. Respir Med 2003; 97: 1303-12.
77. Price D, Yawn B, Brusselle G, Rossi A,. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 2013; 22: 92-100.